Semanteon Capital Management LP Invests $567,000 in IDEXX Laboratories, Inc. $IDXX

Semanteon Capital Management LP purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 888 shares of the company’s stock, valued at approximately $567,000.

A number of other large investors have also added to or reduced their stakes in IDXX. Bank of New York Mellon Corp grew its holdings in shares of IDEXX Laboratories by 156.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock worth $778,439,000 after purchasing an additional 884,808 shares in the last quarter. Generation Investment Management LLP bought a new stake in IDEXX Laboratories during the second quarter worth about $304,277,000. Norges Bank acquired a new stake in IDEXX Laboratories during the second quarter worth about $221,955,000. JPMorgan Chase & Co. increased its holdings in IDEXX Laboratories by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after buying an additional 326,348 shares during the period. Finally, Schroder Investment Management Group raised its position in shares of IDEXX Laboratories by 295.1% in the 2nd quarter. Schroder Investment Management Group now owns 315,785 shares of the company’s stock valued at $169,368,000 after buying an additional 235,863 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on IDXX shares. Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Morgan Stanley lifted their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Jefferies Financial Group restated a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Barclays reduced their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Finally, Wall Street Zen raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 7th. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $783.33.

Insider Activity at IDEXX Laboratories

In related news, EVP George Fennell sold 11,345 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total value of $7,337,038.40. Following the sale, the executive vice president directly owned 9,823 shares in the company, valued at $6,352,730.56. This represents a 53.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total transaction of $920,299.68. Following the transaction, the director directly owned 648 shares of the company’s stock, valued at $407,345.76. This represents a 69.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 18,180 shares of company stock worth $11,626,996 over the last three months. Company insiders own 0.98% of the company’s stock.

Key Headlines Impacting IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Analyst support remains a tailwind — multiple firms continue to rate IDXX favorably (Jefferies, BTIG, Barclays among others) and the consensus remains a “Moderate Buy” with a material above‑current price target consensus. That analyst backdrop can support buying interest. Read More.
• Neutral Sentiment: Company fundamentals: IDXX reported a slight EPS miss (by $0.01) for the most recent quarter but beat on revenue (+14% y/y) and provided FY‑2026 EPS guidance of $14.29–$14.80 — guidance is above many near‑term expectations, which is generally constructive for the stock. Read More.
• Neutral Sentiment: Re‑rating narrative: recent commentary (Conestoga/InsiderMonkey, Yahoo syndicated pieces) argues IDXX shares are re‑rating toward historical averages — this is discussion‑driven and could help multiple investors re‑allocate into the name if the argument gains traction. Read More.
• Neutral Sentiment: Comparisons in the sector: valuation/sector pieces (e.g., Zacks comparing SONVY vs IDXX) may influence relative‑value flows but don’t present new company‑specific catalysts. Read More.
• Neutral Sentiment: Short‑interest data posted for February appears to show zero shares / zero days‑to‑cover (likely a reporting anomaly). That suggests no clear short‑squeeze pressure at present but verify with exchange short‑interest releases.
• Negative Sentiment: Insider selling: multiple execs disclosed sizable sales on Feb 17 — Director Sophie Vandebroek sold 1,464 shares (~$628.62 avg) and EVP Michael Erickson sold 5,371 shares (~$627.38 avg). Large insider sales can be read as signal of personal liquidity/positioning and may weigh on near‑term sentiment. Read More. Read More.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $635.66 on Friday. The business has a 50 day moving average of $677.74 and a 200-day moving average of $669.01. The company has a market capitalization of $50.76 billion, a P/E ratio of 48.64, a P/E/G ratio of 3.87 and a beta of 1.67. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company’s revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.